美国 · 平台与数据 · The Motley Fool

Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

来源：The Motley Fool · 美国 1 小时前

A biosimilar approval target and supply-chain fixes set up margin expansion as core growth offsets legacy drug headwinds.

在 The Motley Fool 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

推荐阅读

We stopped helping our neighbors with free home repairs and our friendship cooled. Who’s to blame?

Top Luxury Goods Stocks To Follow Today - October 25th

Britain will not join Canada’s defence bank, source says

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Amazon’s $75 AI wearable hides a bigger $144-a-year bet

TeraWulf CEO Paul Prager Turns Elon Musk’s ‘Stranded Compute’ Warning Into A Buying Pitch